David Eichenbaum

机构：Retina Vitreous Associates of Florida · ORCID：0000-0003-0654-0668

发表论文 91 篇 · 总被引 1977 次 · h-index 22

代表论文

• Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration (2025 · Ophthalmology · 被引 25)
• Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series (2025 · BMJ Open Ophthalmology · 被引 22)
• Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review (2024 · Ophthalmology and Therapy · 被引 19)
• Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema (2024 · JAMA Ophthalmology · 被引 17)
• Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI) (2024 · Eye · 被引 15)
• Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study (2025 · Journal of VitreoRetinal Diseases · 被引 12)